United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $235.95 -0.44%
EPS Growth %: +19.1%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: +19.1%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $1.65, $0.40 better than the analyst estimate of $1.25. Revenue for the quarter came in at $243.82 million versus the consensus estimate of $233.41 million.
United Therapeutics sees FY2013 revenue of $952.4 million to $1.05 billion, versus the consensus of $990.59 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics sees FY2013 revenue of $952.4 million to $1.05 billion, versus the consensus of $990.59 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
- Minerals Technologies (MTX) Tops Q1 EPS by 16c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
